InvestorsHub Logo
Followers 53
Posts 3355
Boards Moderated 0
Alias Born 10/26/2013

Re: antihama post# 2252

Thursday, 07/12/2018 8:30:07 PM

Thursday, July 12, 2018 8:30:07 PM

Post# of 3283
JTO data indicates an increase of 1248 patients, on the EGFR side of things (not HER2), when looking at slide 16 of the SPPI Presentation. Slide 16 shows ~10% of EGFRex20in vs 11.7% of patients for the JTO paper. I might add that the JTO info is the most recent info out there and should be the most accurate. Tagrisso is priced at (last yrs prices) at $153,000/yr. An extra 1248 pts * $153,000 = $191M; that's in addition too what's been calculated previously (see post starting with 2181 for that).